InnoCare Pharma Achieves First Annual Profit on Record Revenue Growth — InnoCare Pharma Limited

Event summary

InnoCare Pharma reported a 135.3% year-on-year revenue growth to RMB 2,375 million in 2025, achieving its first annual profit of RMB 644 million.
The company secured two new drug application (NDA) approvals and enhanced market penetration of core products, including orelabrutinib and tafasitamab.
InnoCare entered into transformative licensing agreements with Zenas and Prolium, with the Zenas deal valued at over US$2 billion.
Research and development investment increased by 16.9% to RMB 952 million, focusing on advancements in Phase III trials and new technology platforms like ADCs and molecular glue.

The big picture

InnoCare Pharma's first annual profit marks a significant milestone in its strategic development, highlighting the company's ability to translate scientific innovations into sustainable long-term growth. The record licensing deal with Zenas underscores the growing global value of InnoCare's core pipeline and its potential to capture market share in both cancer and autoimmune disease therapeutics.

What we're watching

Global Expansion: The pace at which InnoCare can leverage its licensing deals with Zenas and Prolium to accelerate global clinical development of key assets.
Pipeline Advancements: Whether InnoCare can sustain the momentum in advancing multiple Phase III registrational trials and new technology platforms like ADCs and molecular glue.
Revenue Growth: How the company's focus on securing approvals for five to six innovative drugs and advancing three to four products globally will impact its revenue growth in 2026.